A trend barely two years old is already reshaping how an entire generation of consumers thinks about health, pleasure and self-care: GLP-1 medications. According to new forecasting from WGSN’s Intelligence 2030 report, by the end of the decade these treatments will move far beyond weight loss, changing how people manage their bodies, define health and seek reward.
For beauty and wellness brands, the real signal isn’t the drug itself, it’s where spending goes once appetite changes. Research cited in the report found that US households using GLP-1 medication cut grocery spending by over 5% within six months, while apparel spending rose nearly 10%. Beauty follows the same pattern: a recent US survey found that 40% of GLP-1 users buy small “pick-me-up” beauty items when financially stressed, compared with just 16% of non-users. Pleasure, in other words, doesn’t disappear with a smaller appetite, it migrates.
Smaller, richer rituals. As food plays a smaller role in daily reward for some consumers, beauty can step in with transformative textures, discovery and ritual, delivering emotional payoff in small formats rather than big ones.
Reward beyond appetite. Functional fragrance house Hormone Paris is one signal worth watching: scents built around emotional states, calming, lifting, focusing, position fragrance as a tool for mood rather than just scent, offering a form of reward that has nothing to do with eating.
Decoupling health from thinness. As pharmaceutical weight management becomes part of the cultural baseline, WGSN is explicit that inclusive sizing, representation and product design matter more, not less. Smaller bodies should not be positioned as the default proof of health or success.
For independent and emerging brands especially, this is a moment to watch closely rather than chase. The businesses that win won’t necessarily be the ones launching GLP-1-branded products, they’ll be the ones who understand which consumer needs are lasting, and which are just a temporary side effect of today’s drugs.
Source: WGSN, “Intelligence 2030: The GLP-1 Consumer” (2026).